The first quarter of 2021 saw fewer deals than any in recent memory.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
But forecasts of over $3bn in annual peak sales from Viela’s portfolio look steep.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
SEL-212 fails to beat Krystexxa in phase II, but why did Sobi pay $100m for the asset in June and then put it into phase III?
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.